{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:23:08Z","timestamp":1785284588348,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jdcr.2023.07.007","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T12:15:06Z","timestamp":1689596106000},"page":"81-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders"],"prefix":"10.1016","volume":"39","author":[{"given":"Paula","family":"Finnegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Sadlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jdcr.2023.07.007_bib1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2013 part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jdcr.2023.07.007_bib2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2023.07.007_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2023.07.007_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000324344","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in the management of psoriasis and B-chronic lymphocytic leukemia","volume":"3","author":"Balato","year":"2011","journal-title":"Case Rep Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2023.07.007_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14889","article-title":"IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review","volume":"34","author":"Bellinato","year":"2021","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jdcr.2023.07.007_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.jdcr.2023.07.007_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000501993","article-title":"Secukinumab in the treatment of plaque psoriasis in patients with malignancy","volume":"11","author":"Gambardella","year":"2019","journal-title":"Case Rep Dermatol"},{"issue":"7","key":"10.1016\/j.jdcr.2023.07.007_bib8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/ccr3.2225","article-title":"Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis","volume":"7","author":"Ghazanfar","year":"2019","journal-title":"Clin Case Rep"},{"issue":"6","key":"10.1016\/j.jdcr.2023.07.007_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dth.12522","article-title":"Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma","volume":"30","author":"Gkalpakiotis","year":"2017","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jdcr.2023.07.007_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1684\/ejd.2020.3860","article-title":"Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer","volume":"30","author":"Kamiya","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2023.07.007_bib11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s13555-020-00416-5","article-title":"Clinical characteristics of 18 patients with psoriasis and multiple myeloma identified through digital health crowdsourcing","volume":"10","author":"Jin","year":"2020","journal-title":"Dermatol Ther"},{"issue":"sup2","key":"10.1016\/j.jdcr.2023.07.007_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/09546634.2018.1543843","article-title":"Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies","volume":"29","author":"Lasagni","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jdcr.2023.07.007_bib13","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jdcr.2023.07.007_bib14","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.4081\/dr.2022.9282","article-title":"Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis","volume":"14","author":"Mastorino","year":"2022","journal-title":"Dermatol Reports"},{"issue":"12","key":"10.1016\/j.jdcr.2023.07.007_bib15","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1111\/jdv.15775","article-title":"A real-life experience of psoriatic patients with history of cancer treated with biological drugs","volume":"33","author":"Odorici","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jdcr.2023.07.007_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/ijd.13129","article-title":"The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature","volume":"55","author":"Patel","year":"2016","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.jdcr.2023.07.007_bib17","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s13555-022-00797-9","article-title":"Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study","volume":"12","author":"Pellegrini","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jdcr.2023.07.007_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15435","article-title":"Malignant melanoma in a psoriasis patient after sequential treatment with biologics","volume":"35","author":"Peter","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jdcr.2023.07.007_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D327654071","article-title":"Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies","volume":"27","author":"Porcar Saura","year":"2021","journal-title":"Dermatol Online J"},{"issue":"3","key":"10.1016\/j.jdcr.2023.07.007_bib20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/09546634.2021.1886231","article-title":"Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population","volume":"33","author":"Valenti","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jdcr.2023.07.007_bib21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1468-3083.2011.04044.x","article-title":"Safety of treatment with biologics for psoriasis in daily practice: 5-year data","volume":"26","author":"van L\u00fcmig","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jdcr.2023.07.007_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/ced.13630","article-title":"Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma","volume":"44","author":"Wang","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2023.07.007_bib23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2023.07.007_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2013 part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdcr.2023.07.007_bib25","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2023.07.007_bib26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2023.07.007_bib27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.jdcr.2023.07.007_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirina","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2023.07.007_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2023.07.007_bib30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13555-023-00905-3","article-title":"Use of systemic therapies for treatment of psoriasis in patients with a history of treated solid tumours: inference-based guidance from a Multidisciplinary Expert Panel","volume":"13","author":"Papp","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jdcr.2023.07.007_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.696597","article-title":"Systematic review and recommendations to combine newer therapies with conventional therapy in psoriatic disease","volume":"8","author":"Arora","year":"2021","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.jdcr.2023.07.007_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2023.07.007_bib33","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2023.07.007_bib34","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/ijd.15093","article-title":"Apremilast in patients with history of malignancy: a real-life, single-center experience","volume":"60","author":"Di Lernia","year":"2021","journal-title":"Int J Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623002539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623002539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:25:28Z","timestamp":1762475128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512623002539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":34,"alternative-id":["S2352512623002539"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.07.007","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}